THE SCIENCE OF HORMONAL HEALTH
Hormone health,
made youthful.
Perimenopause, menopause, low testosterone and thyroid health, explained with current evidence, including the FDA’s 2025 hormone therapy label changes, by a quadruple board-certified physician.
Perimenopause
Menopause
Hot flashes & sleep
Bone density
Heart health
Brain & mood
Genitourinary health
Low testosterone
Thyroid
Timing hypothesis
START WHERE YOU ARE
Six ways into the library
Every guide is written and reviewed by Farhan Tahir, MD, and cites the evidence behind it.
01
Conditions
Perimenopause, hot flashes, low T, thyroid disease and more.
Explore →
02
Medications
How each hormone and non-hormonal medicine works, and its evidence.
Explore →
03
Tests & imaging
What your labs and scans measure, and when they mislead.
Explore →
04
Living well
Sleep, strength, nutrition, mood and heart health through midlife.
Explore →
05
Video library
Physician-taught lessons with animated explainers.
Explore →
06
For clinicians
Guideline-based prescribing and monitoring summaries.
Explore →
Hormonal health
Hormones, in balance.
Perimenopause, menopause, testosterone and thyroid. The life stages and lab work behind hormonal health.
Perimenopause support
Menopause wellness
Men’s vitality
Thyroid labs
Sleep & mood
Strength & bone
Hormone panel review
Physician consultation
Energy & focus
Partner wellness
Active midlife
Nutrition for hormones
OUR THESIS
Hormone care moved on. The headlines didn’t.
In 2002, the Women’s Health Initiative linked hormone therapy to breast cancer, heart attacks and strokes, and prescriptions collapsed almost overnight. Its participants averaged 63 years old, most were more than a decade past menopause, and they used older formulations. Re-analysis by age and timing tells a more nuanced story.
Youthful Hormones translates that evidence for midlife women, men and the clinicians who care for them: what hormones do, when treatment helps, when it doesn’t, and how to weigh the trade-offs with your own doctor.
WHAT CHANGED IN 2025
Fear-based warnings come off the label
On November 10, 2025, the FDA moved to remove boxed warnings about heart disease, breast cancer and probable dementia from menopausal hormone therapy, and to recommend starting systemic therapy before 60 or within 10 years of menopause.
WHAT DIDN’T CHANGE
Individual risk still matters
Women with a uterus still need a progestogen with systemic estrogen, the endometrial cancer warning stays, and a history of breast cancer, blood clots, stroke or heart disease still calls for specialist review.
Sources: U.S. FDA announcement, November 10, 2025; The Menopause Society 2022 Hormone Therapy Position Statement.
MIDLIFE HORMONES, IN NUMBERS
Common, long-lasting and under-treated.
Up to 80%
of women have hot flashes or night sweats during the menopause transition
Avis et al., JAMA Intern Med 2015
7.4 years
median duration of frequent hot flashes and night sweats
SWAN, Avis et al., JAMA Intern Med 2015
2025
the year the FDA moved to remove boxed warnings from hormone therapy labels
U.S. FDA, November 10, 2025
0.96
hazard ratio for major cardiac events, testosterone vs placebo, in TRAVERSE
Lincoff et al., NEJM 2023
THE HORMONE LIFECYCLE
How hormones change, decade by decade.
Estradiol, progesterone and testosterone follow very different arcs across life. Perimenopause is the most turbulent stretch, when levels swing before they fall. Drag the slider to explore each stage.
Illustrative shapes of typical patterns, not laboratory reference ranges. Monthly cycles are compressed for display. Drag the slider to explore each life stage.
WHAT WE COVER
Eight areas where hormones shape health.
Hormones touch nearly every system. These are the areas where midlife changes are most common, most treatable and most misunderstood.
01
Perimenopause
Irregular cycles, swinging estradiol and falling progesterone can bring hot flashes, poor sleep and mood changes years before the final period.
02
Menopause & hot flashes
The brain’s temperature center becomes unstable as estrogen falls. Hormonal and non-hormonal treatments now both target it directly.
03
Bone health
Bone loss speeds up in the years around menopause. Estrogen helps prevent it, and a DXA scan finds risk early.
04
Heart & metabolism
LDL cholesterol, ApoB, blood pressure and belly fat tend to rise after menopause, making midlife the moment to act on cardiovascular risk.
05
Brain, mood & sleep
Night sweats fragment sleep, and the transition carries a higher risk of depressive symptoms. Both are treatable.
06
Genitourinary health
Dryness, painful sex, urgency and recurrent infections tend to progress without treatment. Low-dose vaginal estrogen helps most women.
07
Men’s testosterone
True deficiency means symptoms plus repeatedly low morning levels. Treatment can help, but it is not anti-aging medicine.
08
Thyroid
Thyroid disorders are common in midlife and can mimic menopause. TSH and free T4 tell them apart.
CONDITION GUIDES
Start with the condition
Menopause & bone
Perimenopause
The years of shifting hormones before the final period, often bringing cycle changes, hot flashes, poor sleep and mood changes.
Read the guide →
Menopause & bone
Menopause & hot flashes
Why falling estrogen switches on the brain's heat-loss alarm, and the treatments that switch it off.
Read the guide →
Menopause & bone
Genitourinary syndrome of menopause
Dryness, painful sex and urinary symptoms from low estrogen. Common, progressive and very treatable.
Read the guide →
Reproductive & sexual health
Polycystic ovary syndrome
A common hormone condition linking irregular cycles, androgen excess and insulin resistance, with lifelong metabolic effects.
Read the guide →
Reproductive & sexual health
Male hypogonadism
Symptoms plus confirmed low testosterone. Diagnosis and fertility come first, then treatment.
Read the guide →
Thyroid
Hypothyroidism & Hashimoto's
When the thyroid makes too little hormone, everything slows. Levothyroxine restores it reliably.
Read the guide →
THE TIMING HYPOTHESIS
When you start matters.
The benefits and risks of systemic hormone therapy depend on age and on how long it has been since menopause. Move the sliders to see where a starting point falls.
For bothersome hot flashes or to prevent bone loss, and with no contraindications, The Menopause Society (2022) considers the benefit-risk ratio favorable for women under 60 or within 10 years of menopause. Updated FDA labeling (2025) also recommends starting systemic therapy in this window.
At any age, a history of breast or endometrial cancer, unexplained vaginal bleeding, blood clots, stroke, heart disease or active liver disease needs specialist review first.
Educational tool, not medical advice. Sources: The Menopause Society 2022 Hormone Therapy Position Statement; FDA labeling update, November 2025.
OUR STANCE ON “BIOIDENTICAL” HORMONES
FDA-approved first. Compounded only when needed.
FDA-approved estradiol and micronized progesterone are already chemically identical to the hormones your body makes, and they come with tested purity, consistent dosing and safety labeling.
A 2020 National Academies report found insufficient evidence to support the safety and effectiveness of compounded bioidentical hormone therapy and recommended restricting its use. Compounding still has a role when someone is allergic to an ingredient or needs a dose no approved product offers.
Source: National Academies of Sciences, Engineering, and Medicine. The Clinical Utility of Compounded Bioidentical Hormone Therapy, 2020.
TREATMENTS
Every option, with its evidence.
FDA-approved
Transdermal & oral estradiol
The most effective treatment for hot flashes and night sweats.
Read the evidence →
FDA-approved
Vaginal estrogen
Local relief for genitourinary symptoms.
Read the evidence →
FDA-approved
Elinzanetant (Lynkuet)
A dual NK1/NK3 blocker for hot flashes and sleep.
Read the evidence →
FDA-approved
Testosterone therapy for men
For confirmed deficiency, not just a low number.
Read the evidence →
RESEARCH DESK
What’s new in hormone science.
Regulatory
·
FDA moves to remove boxed warnings from menopause hormone therapy
HHS and the FDA announced they will remove boxed warnings about cardiovascular disease, breast cancer and probable dementia from more than 20 menopausal hormone therapy products, while keeping the warning about endometrial cancer for systemic estrogen used alone.
Regulatory action
Approvals
·
FDA approves elinzanetant (Lynkuet), a dual NK1/NK3 blocker for hot flashes
The FDA approved Bayer’s elinzanetant, a once-nightly non-hormonal capsule for moderate to severe hot flashes and night sweats caused by menopause.
Phase 3 RCTs
Clinical Trials
·
TRAVERSE: testosterone does not raise major cardiac events in men with hypogonadism
In 5,246 men aged 45 to 80 with low testosterone and existing or high risk of cardiovascular disease, testosterone gel was noninferior to placebo for heart attack, stroke and cardiovascular death.
Human RCT
FROM THE STUDIO
Video lessons
Short lessons with Dr. Tahir, each paired with an animated explainer.
8 min
Perimenopause, Explained
What's happening to your hormones in your 40s, why symptoms come and go, and when to get help.
Watch the lesson →
6 min
Hot Flashes: What's Happening in Your Brain
The neuroscience of hot flashes and how new medicines target the brain's thermostat.
Watch the lesson →
10 min
Hormone Therapy After the Label Change
What the FDA's boxed-warning update means, what the WHI really showed, and who benefits from HT today.
Watch the lesson →
WHO THIS IS FOR
One evidence base, three ways in.
FOR WOMEN IN MIDLIFE
Make sense of the transition
What perimenopause and menopause do to your body, which treatments work, and how to talk with your clinician about timing and risk.
Start with the science →
FOR MEN
Low testosterone, without the hype
How deficiency is diagnosed, what TRAVERSE showed about heart safety, and the trade-offs that matter, including fertility.
Compare treatments →
FOR CLINICIANS
Primary sources, labeled
Evidence labels, trial context and regular research updates you can share with patients.
Read the research →
WHY WE BUILT THIS
“Hormone care should be individualized, evidence-based and free of fear. That means honest conversations about benefits, risks and timing.”
Farhan Tahir, MD · Founder, Youthful Vitality & Longevity Medicine®
Farhan Tahir, MD, FACR, Dip. ABOM
FOUNDER & MEDICAL EDITOR
Quadruple board-certified in internal medicine, rheumatology, integrative medicine and obesity medicine, with more than 20 years of practice across academic, hospital, infusion and telemedicine settings. He leads Youthful Vitality & Longevity Medicine in Doylestown, PA and Manhattan.
THE YOUTHFUL HORMONES BRIEF
The science of hormones, in your inbox every two weeks.
New research decoded in five minutes, with evidence labels and zero hype. We never sell or share your information.
Educational content only. Unsubscribe anytime.